tbuckley/cabot-search huggingface dataset:
Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD)
Authors: Kiran K. Mirza, Mariusz K. Szymanski, Thomas Schmidt, Nicolaas de Jonge, Darshan H. Brahmbhatt, Filio Billia, Steven Hsu, Guy A. MacGowan, Djordje G. Jakovljevic, Piergiuseppe Agostoni, Filippo Trombara, Ulrich Jorde, Yogita Rochlani, Katrien Vandersmissen, Nils Reiss, Stuart D. Russell, Bart Meyns, Finn Gustafsson
Journal: JACC Heart Failure (2021)
First Treatment for Plasminogen Deficiency Is Approved
Authors: Bridget M. Kuehn
Journal: JAMA (2021)

Purified plasminogen that’s derived from human plasma has become the first FDA-approved treatment for plasminogen deficiency type 1. Plasminogen, human-tvmh, marketed as Ryplazim, is administered intravenously every 2 to 4 days.
P-189 Safety and feasibility of liposomal irinotecan for unresectable pancreatic adenocarcinoma: Real-world experience in a Japanese cohort
Authors: A. Sakai, I. Yoshioka, K. Shibuya, T. Hanaoka, T. Ando, K. Hirano, T. Watanabe, S. Kajiura, K. Takahashi, S. Sawada, T. Bando, Y. Tohmatsu, N. Kimura, T. Igarashi, T. Miwa, S. Hojo, K. Matsui, T. Okumura, I. Yasuda, T. Fujii
Journal: Annals of Oncology (2021)
PCIとCABG:Shinkenデータベース2004-2011からの実世界
Authors: Tanabe Hiroaki, Suzuki Shinya, Takai Hideaki, Kadoma Yoshitaka, Yamabe Takeshi, Kanou Hiroto, Matsuno Shunsuke, Ootsuka Takayuki, Uejima Tokuhisa, Oikawa Yuuji, Koike Akira, Nagashima Kazuyuki, Kirigaya Hajime, Sagara Kouichi, Sawada Hitoshi, Aizawa Tadanori, Yasjima Jyunnji, Yamashita Takeshi
Journal: Circulation (2013)
Pembrolizumab
Authors: Leila Khoja, Marcus O. Butler, S. Peter Kang, Scot Ebbinghaus, Anthony M. Joshua
Journal: Journal for ImmunoTherapy of Cancer (2015)

The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in melanoma and a variety of other tumor types. Pembrolizumab was the first anti-PD-1 antibody to be approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma with disease progression following ipilimumab, and if <i>BRAF</i><sup>V600</sup> mutation positive, a BRAF inhibitor. Pembrolizumab has also received breakthrough status for the treatment of <i>EGFR</i> mutation-negative, <i>ALK</i> rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based chemotherapy. There remain a number of pivotal trials in progress to further evaluate the optimal use of pembrolizumab alone and in combination for melanoma, NSCLC, and other tumor types. In this article, we review the efficacy and toxicity profile of pembrolizumab and evaluate its future development.
Recommendations for nomenclature and definition of cell products intended for human cardiovascular use
Authors: Doris A Taylor, Lourdes Chacon-Alberty, Luiz C Sampaio, Mariana Gonzalez del Hierro, Emerson C Perin, Fernanda C P Mesquita, Timothy D Henry, Jay H Traverse, Carl J Pepine, Joshua M Hare, Michael P Murphy, Phillip C Yang, Keith L March, Rachel W Vojvodic, Ray F Ebert, Roberto Bolli
Journal: Cardiovascular Research (2021)

Abstract Exogenous cell-based therapy has emerged as a promising new strategy to facilitate repair of hearts damaged by acute or chronic injury. However, the field of cell-based therapy is handicapped by the lack of standardized definitions and terminology, making comparisons across studies challenging. Even the term ‘stem cell therapy’ is misleading because only a small percentage of cells derived from adult bone marrow, peripheral blood, or adipose tissue meets the accepted haematopoietic or developmental definition of stem cells. Furthermore, cells (stem or otherwise) are dynamic biological products, meaning that their surface-marker expression, phenotypic and functional characteristics, and the products they secrete in response to their microenvironment can change. It is also important to point out that most surface markers are seldom specific for a cell type. In this article, we discuss the lack of consistency in the descriptive terminology used in cell-based therapies and offer guidelines aimed at standardizing nomenclature and definitions to improve communication among investigators and the general public.
2030年までのシナリオに基づく予測による1990年と2017年の間の新生児死亡率における国家的,地域的,全体的レベルと傾向:系統的分析【JST・京大機械翻訳】
Authors: Hug Lucia, Alexander Monica, You Danzhen, Alkema Leontine
Journal: The Lancet Global Health (2019)
Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations)
Authors: Jeffrey L. Anderson, Jonathan L. Halperin, Nancy M. Albert, Biykem Bozkurt, Ralph G. Brindis, Lesley H. Curtis, David DeMets, Robert A. Guyton, Judith S. Hochman, Richard J. Kovacs, E. Magnus Ohman, Susan J. Pressler, Frank W. Sellke, Win-Kuang Shen
Journal: Circulation (2013)
P-231 Systemic inflammatory biomarkers and their association with survival in gastroesophageal cancer patients: A retrospective single-center analysis
Authors: H. Puhr, J. Takats, L. Jahic, D. Kuchling, M. Paireder, R. Asari, A. Berghoff, M. Preusser, A. Ilhan-Mutlu
Journal: Annals of Oncology (2021)
Covid 19: Most patients in England received good or excellent care in hospital, finds analysis
Authors: Adrian O’Dowd
Journal: BMJ (2021)

Covid 19: Most patients in England received good or excellent care in hospital, finds analysis Adrian O'Dowd Most patients admitted to hospitals in England with SARS-CoV-2 in 2020 received good care despite the challenges of dealing with a new disease, according to a review produced by the Royal College of Physicians (RCP). 1 1 Royal College of Physicians.Caring for hospital patients with covid-19: quality of care in England examined by case record review. 2 August 2021.www.rcplondon.ac.
老化免疫系の包括的プロファイリングは炎症の保存されたホールマークとしてクローンGZMK+CD8+T細胞を明らかにする【JST・京大機械翻訳】
Authors: A Mogilenko Denis, Shpynov Oleg, Andhey Prabhakar Sairam, Arthur Laura, Swain Amanda, Esaulova Ekaterina, Brioschi Simone, Shchukina Irina, Kerndl Martina, Bambouskova Monika, Yao Zhangting, Laha Anwesha, Zaitsev Konstantin, Burdess Samantha, Gillfilan Susan, A Stewart Sheila, Colonna Marco, N Artyomov Maxim
Journal: Immunity (2021)
A neurovascular-unit-on-a-chip for the evaluation of the restorative potential of stem cell therapies for ischaemic stroke
Authors: Zhonglin Lyu, Jon Park, Kwang-Min Kim, Hye-Jin Jin, Haodi Wu, Jayakumar Rajadas, Deok-Ho Kim, Gary K. Steinberg, Wonjae Lee
Journal: Nature Biomedical Engineering (2021)
Free Papers
Authors: D. Matamis, D. Lagonidis, M. Tsagourias, D. Riggos, P. Pelosi, M. Croci, D. Chiumello, L. Gattinoni, M. Borelli, L. Lampati, E. Vascotto, M. Verweij, R. Brambilla, S. Elia, A. Pesenti, H. Reissmann, O. Katzenstein, A. Prause, B. Fuellekrug, W. Pothmann, N. Brienza, S. Grasso, F. Bruno, M. Dambrosio, G. Cinnella, V. M. Ranieri, V. Lagioia, A. Brienza, K. Vaiĉiulis, T. Bagdonaviĉiené, K. Dapŝys, G. Žukauskas, F. Thys, P. Eggimann, P. Jolliet, J. M. Thouret, J. Pugin, J. C. Chevrolet, M. Max, U. Kaisers, V. Eichhorn, S. Böhm, R. Rossaint, B. Lachmann, J. L. G. Amaral, M. M. Ito, M. Munechika, J-J. Rouby, G. A. J. Amarante, D. Ferez, J. Mancebo, P. Albaladejo, E. Bak, S. Elatrous, D. Touchard, M. Subirana, F. Lemaire, A. Harf, L. Brochard, P. Aslanian, G. Lopez, M. Pérez, A. J. Betbesé, G. Rialp, J. A. Santos, J. Ballús, A. Net, G. Bonmarchand, V. Chevron, Y. Lacoume, F. Tamion, G. Girault, B. Temmesfeld, A. Günther, D. Walmrath, C. Siebert, F. Grimminger, W. Seeger, G. B. McBride, G. Lavery, F. Valenza, A. Pedoto, S. Crotti, D. Mascheroni, L. Gattinoni, H. Ruiz-Bailén, H. Colmenero-Ruiz, A. Cárdenas-Cruz, I. Navarrete-Sánchez, A. Bayona-Gómez, E. Fernández-Mondejar, R. Nekvasil, R. Trittenwein, M. Fedora
Journal: Intensive Care Medicine (1996)
Covid-19 laboratory leak hypothesis: a convenient scapegoat
Authors: Colin Bannon
Journal: BMJ (2021)

<h3>Introduction</h3> Medical devices (MedDevs) and medicines are assessed (and monitored) differently before and after launch. There are products for repeated oral ingestion that are marketed in the European Union as MedDevs. <h3>Objectives and methods</h3> To illustrate the consequences of these differences in assessment, we compared the leaflet information of three MedDevs with the standards for medicines and with published evidence at launch. As examples, gelatin tannate (GT), its combination with tyndalised probiotics (TP) (GTTP) for diarrhoea and a gel containing hyaluronic acid (HA)/chondroitin sulfate (CS)/poloxamer (Pol407) (HACSPol) for gastro-oesophageal reflux disease were examined. <h3>Results</h3> Applying standards for medicines, product composition is insufficiently defined in the MedDev leaflet (eg, plant origin, polymerisation grade, dose and ratio of the relevant constituents). As no age limit is mentioned in the leaflets, all 3 products allow use in children from birth onwards, although published clinical documentation in children was poor (GT) or lacking (GTTP and HACSPol). MedDev leaflets do not mention adverse events (AEs), while literature search suggests safety concerns such as tannic acid (TA) cytotoxicity, potentially more diarrhoea/AEs with TP, use of doses higher than established safe (TA and HA) and lack of chronic toxicity studies for oral Pol407. None refers to interactions with medicines, although some ingredients may affect medicine absorption. <h3>Conclusion</h3> Although these MedDevs require repeated oral intake as do medicines, their assessment and monitoring differ significantly from the standards for medicines. Compared with medicines, MedDevs for repeated oral use are poorly labelled and rely on very limited clinical information at market release.
Home modifications to prevent home fall injuries in houses with Māori occupants (MHIPI): a randomised controlled trial
Authors: Michael D Keall, Hope Tupara, Nevil Pierse, Marg Wilkie, Michael G Baker, Philippa Howden-Chapman, Chris Cunningham
Journal: The Lancet Public Health (2021)

BackgroundAs with many Indigenous populations internationally, Māori in New Zealand suffer health inequity. We aimed to assess the rate of fall injuries at home with and without home modifications in houses with Māori occupants.MethodsWe did a single-blind randomised controlled trial in the Wellington and Taranaki regions of New Zealand and enrolled owner-occupied households with at least one Māori occupant. Only households who stated they intended to live at that address for the subsequent 3 years were eligible for participation. We randomly assigned (1:1) households to either the intervention group, who received home modifications (handrails for outside steps and internal stairs, grab rails for bathrooms, outside lighting, repairs to window catches, high-visibility and slip-resistant edging for outside steps, fixing of lifted edges of carpets and mats, non-slip bath mats, and slip-resistant surfacing for outside areas such as decks) immediately, or the control group, who received the modifications 3 years later. Data on home injuries were obtained from the Accident Compensation Corporation and coded by study team members, who were masked to study group allocation. The primary outcome was the rate of medically treated fall injuries at home per household per year, analysed according to intention to treat. This Māori Home Injury Prevention Intervention (MHIPI) trial is now completed, and is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12613000148774.FindingsBetween Sept 3, 2013, and Oct 1, 2014, 824 households were assessed for eligibility and 254 were enrolled, of which 126 (50%) were assigned to the intervention group and 128 (50%) were assigned to the control group. After adjustment for previous falls and geographical region, there was an estimated 31% reduction in the rate of fall injuries at home per year exposed to the intervention compared with households in the control group (adjusted relative rate 0·69 [95% CI 0·47–1·00]).InterpretationLow-cost home modifications and repairs can be an effective means to reduce injury disparities. The high prevalence of modifiable safety issues in Māori homes merits considerable policy and community effort.FundingHealth Research Council of New Zealand.
Abstract 14642: Calcium Calmodulin Dependent Protein Kinase II Overexpression Predisposes Myocytes to Isoproterenol-Induced Early Afterdepolarizations Before the Onset of Heart Failure
Authors: Andrew G Edwards, Johan Hake, Joan Heller Brown, Andrew D McCulloch
Journal: Circulation (2011)

BACKGROUND: Hyperactivity of Ca2+-Calmodulin dependent protein kinase II (CaMKII) occurs in human HF, and transgenic mice expressing CaMKIIδc (CaMKIIδc TG) exhibit afterdepolarizations and triggere...
HCC : Serum interleukin-6 and high-sensitivity C-reactive protein as a prognostic indicator in hepatocellular carcinoma (초)
Authors: Byong Sun Oh, Jeong Won Jang, Jung Hyun Kwon, Chan Ran You, Sun Hong Yoo, Chang Don Lee, Chul Seung Kay, Hyun Suk Jung, Kyu Won Chung
Journal: Clinical and Molecular Hepatology (2011)
Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN
Authors: Yuri Gorelik, Shay Freilich, Shiran Gerassy-Vainberg, Sigal Pressman, Chagit Friss, Alexandera Blatt, Gili Focht, Yiska Loewenberg Weisband, Shira Greenfeld, Revital Kariv, Nathan Lederman, Iris Dotan, Naama Geva-Zatorsky, Shai Shlomo Shen-Orr, Yechezkel Kashi, Yehuda Chowers
Journal: Gut (2021)

Anti-drug antibodies (ADA) to anti-tumour necrosis factor (anti-TNF) therapy drive treatment loss of response. An association between intestinal microbial composition and response to anti-TNF therapy was noted. We therefore aimed to assess the implications of antibiotic treatments on ADA formation in patients with inflammatory bowel disease (IBD).We analysed data from the epi-IIRN (epidemiology group of the Israeli IBD research nucleus), a nationwide registry of all patients with IBD in Israel. We included all patients treated with anti-TNF who had available ADA levels. Survival analysis with drug use as time varying covariates were used to assess the association between antibiotic use and ADA development. Next, specific pathogen and germ-free C57BL mice were treated with respective antibiotics and challenged with infliximab. ADA were assessed after 14 days.Among 1946 eligible patients, with a median follow-up of 651 days from initiation of therapy, 363 had positive ADA. Cox proportional hazard model demonstrated an increased risk of ADA development in patients who used cephalosporins (HR=1.97, 95% CI 1.58 to 2.44), or penicillins with β-lactamase inhibitors (penicillin-BLI, HR=1.4, 95% CI 1.13 to 1.74), whereas a reduced risk was noted in patients treated with macrolides (HR=0.38, 95% CI 0.16 to 0.86) or fluoroquinolones (HR=0.20, 95% CI 0.12 to 0.35). In mice exposed to infliximab, significantly increased ADA production was observed in cephalosporin as compared with macrolide pretreated mice. Germ-free mice produced no ADA.ADA production is associated with the microbial composition. The risk of ADA development during anti-TNF therapy can possibly be reduced by avoidance of cephalosporins and penicillin-BLIs, or by treatment with fluoroquinolones or macrolides.
Prognostic Value of Cortisol Response in Septic Shock
Authors: Paul Marik
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells
Authors: Qiufen Zhang, Yingyi Chen, Duan Ni, Zhimin Huang, Jiacheng Wei, Li Feng, Jun-Cheng Su, Yingqing Wei, Shaobo Ning, Xiuyan Yang, Mingzhu Zhao, Yuran Qiu, Kun Song, Zhengtian Yu, Jianrong Xu, Xinyi Li, Houwen Lin, Shaoyong Lu, Jian Zhang
Journal: Acta Pharmaceutica Sinica B (2021)

SIRT6 belongs to the conserved NAD+-dependent deacetylase superfamily and mediates multiple biological and pathological processes. Targeting SIRT6 by allosteric modulators represents a novel direction for therapeutics, which can overcome the selectivity problem caused by the structural similarity of orthosteric sites among deacetylases. Here, developing a reversed allosteric strategy AlloReverse, we identified a cryptic allosteric site, Pocket Z, which was only induced by the bi-directional allosteric signal triggered upon orthosteric binding of NAD+. Based on Pocket Z, we discovered an SIRT6 allosteric inhibitor named JYQ-42. JYQ-42 selectively targets SIRT6 among other histone deacetylases and effectively inhibits SIRT6 deacetylation, with an IC50 of 2.33 μmol/L. JYQ-42 significantly suppresses SIRT6-mediated cancer cell migration and pro-inflammatory cytokine production. JYQ-42, to our knowledge, is the most potent and selective allosteric SIRT6 inhibitor. This study provides a novel strategy for allosteric drug design and will help in the challenging development of therapeutic agents that can selectively bind SIRT6.
Host adaptation in gut Firmicutes is associated with sporulation loss and altered transmission cycle
Authors: Hilary P. Browne, Alexandre Almeida, Nitin Kumar, Kevin Vervier, Anne T. Adoum, Elisa Viciani, Nicholas J. R. Dawson, Samuel C. Forster, Claire Cormie, David Goulding, Trevor D. Lawley
Journal: Genome biology (2021)

Abstract Background Human-to-human transmission of symbiotic, anaerobic bacteria is a fundamental evolutionary adaptation essential for membership of the human gut microbiota. However, despite its importance, the genomic and biological adaptations underpinning symbiont transmission remain poorly understood. The Firmicutes are a dominant phylum within the intestinal microbiota that are capable of producing resistant endospores that maintain viability within the environment and germinate within the intestine to facilitate transmission. However, the impact of host transmission on the evolutionary and adaptive processes within the intestinal microbiota remains unknown. Results We analyze 1358 genomes of Firmicutes bacteria derived from host and environment-associated habitats. Characterization of genomes as spore-forming based on the presence of sporulation-predictive genes reveals multiple losses of sporulation in many distinct lineages. Loss of sporulation in gut Firmicutes is associated with features of host-adaptation such as genome reduction and specialized metabolic capabilities. Consistent with these data, analysis of 9966 gut metagenomes from adults around the world demonstrates that bacteria now incapable of sporulation are more abundant within individuals but less prevalent in the human population compared to spore-forming bacteria. Conclusions Our results suggest host adaptation in gut Firmicutes is an evolutionary trade-off between transmission range and colonization abundance. We reveal host transmission as an underappreciated process that shapes the evolution, assembly, and functions of gut Firmicutes.
Microglial inclusions and neurofilament light chain release follow neuronal α-synuclein lesions in long-term brain slice cultures
Authors: Melanie Barth, Mehtap Bacioglu, Niklas Schwarz, Renata Novotny, Janine Brandes, Marc Welzer, Sonia Mazzitelli, Lisa M. Häsler, Manuel Schweighauser, Thomas V. Wuttke, Deborah Kronenberg-Versteeg, Karina Fog, Malene Ambjørn, Ania Alik, Ronald Melki, Philipp J. Kahle, Derya R. Shimshek, Henner Koch, Mathias Jucker, Gaye Tanriöver
Journal: Molecular Neurodegeneration (2021)

Proteopathic brain lesions are a hallmark of many age-related neurodegenerative diseases including synucleinopathies and develop at least a decade before the onset of clinical symptoms. Thus, understanding of the initiation and propagation of such lesions is key for developing therapeutics to delay or halt disease progression.Alpha-synuclein (αS) inclusions were induced in long-term murine and human slice cultures by seeded aggregation. An αS seed-recognizing human antibody was tested for blocking seeding and/or spreading of the αS lesions. Release of neurofilament light chain (NfL) into the culture medium was assessed.To study initial stages of α-synucleinopathies, we induced αS inclusions in murine hippocampal slice cultures by seeded aggregation. Induction of αS inclusions in neurons was apparent as early as 1week post-seeding, followed by the occurrence of microglial inclusions in vicinity of the neuronal lesions at 2-3 weeks. The amount of αS inclusions was dependent on the type of αS seed and on the culture's genetic background (wildtype vs A53T-αS genotype). Formation of αS inclusions could be monitored by neurofilament light chain protein release into the culture medium, a fluid biomarker of neurodegeneration commonly used in clinical settings. Local microinjection of αS seeds resulted in spreading of αS inclusions to neuronally connected hippocampal subregions, and seeding and spreading could be inhibited by an αS seed-recognizing human antibody. We then applied parameters of the murine cultures to surgical resection-derived adult human long-term neocortical slice cultures from 22 to 61-year-old donors. Similarly, in these human slice cultures, proof-of-principle induction of αS lesions was achieved at 1week post-seeding in combination with viral A53T-αS expressions.The successful translation of these brain cultures from mouse to human with the first reported induction of human αS lesions in a true adult human brain environment underlines the potential of this model to study proteopathic lesions in intact mouse and now even aged human brain environments.
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
Authors: Maria Prendecki, Candice Clarke, Helena Edwards, Stacey McIntyre, Paige Mortimer, Sarah Gleeson, Paul Martin, Tina Thomson, Paul Randell, Anand Shah, Aran Singanayagam, Liz Lightstone, Alison Cox, Peter Kelleher, Michelle Willicombe, Stephen P McAdoo
Journal: Annals of the Rheumatic Diseases (2021)

There is an urgent need to assess the impact of immunosuppressive therapies on the immunogenicity and efficacy of SARS-CoV-2 vaccination.
Reducing risk of childhood obesity in the wake of covid-19
Authors: Alexandra Chung, Louise Tully, Sarah Czernin, Rachel Thompson, Athar Mansoor, Steven L Gortmaker
Journal: BMJ (2021)

Reducing risk of childhood obesity in the wake of covid-19Alexandra Chung and colleagues call for governments to prioritise child obesity as they implement measures to recover from the pandemic • Priorities include promotion of healthy school food and physical activity environments, reducing exposure to unhealthy food marketing, and taxation of sugar sweetened beverages on 14 July